JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis
- 6 June 2013
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 368 (23), 2240-2241
- https://doi.org/10.1056/nejmc1214233
Abstract
JC virus in the peripheral circulation increases the risk of PML among natalizumab-treated patients. In this study, a PCR assay detected viral DNA, an indication of infection, in some persons in whom tests for seropositivity for antibodies to the virus were negative.Keywords
This publication has 5 references indexed in Scilit:
- Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal LeukoencephalopathyPLoS Pathogens, 2012
- Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohortNeurology, 2012
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2012
- ReplyAnnals of Neurology, 2011
- JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2010